Introduction
Haemovigilance (or blood surveillance) aims to ensure and improve the quality and safety of blood and blood components, as well as the safety of their administration.
To achieve this objective, data related to serious adverse reactions linked to the donation or transfusion of blood and blood components, as well as serious incidents likely to affect the quality and safety of labile blood components, are recorded and evaluated.
Since 22 April 2011, haemovigilance contact persons in blood establishments and healthcare institutions have been able to report serious adverse reactions and incidents to the FAMHP via an online form. In March 2026, this system was replaced by the HemoVigilance web application.
Backup forms
When the HemoVigilance application is temporarily unavailable, haemovigilance contact persons may use Word forms.
• For hospitals
Notification and confirmation forms for a serious adverse incident (version FR/version NL)
Notification and confirmation forms for a serious adverse reaction (version FR/version NL)
• For blood establishments/centres
Notification and confirmation forms for a serious adverse incident (version FR/version NL)
Notification and confirmation forms for a serious adverse reaction (version FR/version NL)
More information
User guide for the HemoVigilance application (version FR/version NL)
User guide - Access to the FAMHP portal (version FR/version NL)
Contact
hemovigil@fagg-afmps.be